OmniAb Partners with ArrowMark and Viking Global Investors on Antibody Discovery Agreement

OmniAb has entered into a license and services agreement with Mabtrx Biosciences, a subsidiary of ArrowMark Partners and Viking Global Investors. The agreement involves OmniAb providing antibody discovery services for targets defined by Mabtrx, with potential equity and royalties for the discovery of novel antibodies. This partnership highlights OmniAb's ability to leverage its transgenic chicken-based technologies to deliver value across different time horizons.